Journal article
Tranexamic acid in patients undergoing coronary-artery surgery
PS Myles, JA Smith, A Forbes, B Silbert, M Jayarajah, T Painter, DJ Cooper, S Marasco, J McNeil, JS Bussieres, S McGuinness, K Byrne, MTV Chan, G Landoni, S Wallace
New England Journal of Medicine | Published : 2017
Abstract
BACKGROUND Tranexamic acid reduces the risk of bleeding among patients undergoing cardiac surgery, but it is unclear whether this leads to improved outcomes. Furthermore, there are concerns that tranexamic acid may have prothrombotic and proconvulsant effects. METHODS In a trial with a 2-by-2 factorial design, we randomly assigned patients who were scheduled to undergo coronary-artery surgery and were at risk for perioperative complications to receive aspirin or placebo and tranexamic acid or placebo. The results of the tranexamic acid comparison are reported here. The primary outcome was a composite of death and thrombotic complications (nonfatal myocardial infarction, stroke, pulmonary emb..
View full abstractGrants
Funding Acknowledgements
Funded by the Australian National Health and Medical Research Council and others; ATACAS Australia New Zealand Clinical Trials Registry number, ACTRN12605000557639.)